EGF and gastric cancer: further demonstrated that PRKG1 inhibits the epidermal growth factor‐induced MAPK/ERK signalling pathway, reducing the invasive and proliferative capabilities of gastric cancer cells, suggesting PRKG1 as a potential therapeutic target.